*For medical professionals reading reference only
Please look forward to the China Chest Cancer Conference
Lung cancer, the malignant tumor with the highest incidence and mortality rate in my country, seriously threatening the lives and health of Chinese residents.
With the development of diagnosis and treatment technology and drugs, targeted therapy and immunotherapy have brought longer overall survival (OS) to lung cancer patients. However, there are still many unsolved problems in the field of lung cancer.
EGFR-TKI, as a first-line treatment plan for EGFR mutation-positive lung cancer, has fully confirmed its efficacy. Third-generation EGFR-TKI brings patients a median OS of 39 months. Some patients with lung cancer who have progressed after third-generation EGFR-TKI treatment may experience acquired mutations. Its treatment strategy needs to be further explored.
Lung large cell neuroendocrine carcinoma is a special subtype of lung large cell carcinoma . Its pathological diagnosis is difficult and its prognosis is poor. Even in the early stages, the 5-year survival rate after surgical resection is low.
This period of the China Chest Tumor Conference discussed in-depth discussions on "Treatment options for large-cell neuroendocrine cancer" and "Cases of secondary KRAS G12C mutations after the treatment of EGFR mutant lung adenocarcinoma".
Scan the QR code above to enter the doctor station app
Based on the successful holding of the "Guangdong Grand Consultation" in 2021, in order to gather the wisdom of experts on a larger scale and promote the multidisciplinary expert diagnosis and treatment model of lung cancer more widely, the Lung Oncology Branch of the Guangdong Medical Association and the Guangdong Clinical Trial Association/China Chest Oncology Research Assistance Group (GACT/CTONG) took the lead in organizing the "China Chest Oncology Consultation" activity from February 2022. We invite experts from all majors in the field of chest tumor treatment across the country to form a consultation and decision-making team, and conduct multidisciplinary consultations on representative difficult cases of lung cancer every month, gather the sword of everyone's wisdom, and pick up the shield of evidence-based medicine to contribute to the key tasks of lung cancer diagnosis and treatment in China.
On October 15, the eighth conference of , which is broadcast on the entire network of , is about to come, and experts from various disciplines will have another warm and passionate discussion. Welcome to watch and communicate.
*This article is only used to provide scientific information to medical personnel and does not represent the views of this platform
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-